BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 15361263)

  • 21. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome.
    Howland RH; Rush AJ; Wisniewski SR; Trivedi MH; Warden D; Fava M; Davis LL; Balasubramani GK; McGrath PJ; Berman SR
    Drug Alcohol Depend; 2009 Jan; 99(1-3):248-60. PubMed ID: 18986774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression.
    Abolfazli R; Hosseini M; Ghanizadeh A; Ghaleiha A; Tabrizi M; Raznahan M; Golalizadeh M; Akhondzadeh S
    Depress Anxiety; 2011 Apr; 28(4):297-302. PubMed ID: 21456039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between obesity and depression: characteristics and treatment outcomes with antidepressant medication.
    Toups MS; Myers AK; Wisniewski SR; Kurian B; Morris DW; Rush AJ; Fava M; Trivedi MH
    Psychosom Med; 2013; 75(9):863-72. PubMed ID: 24163386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
    Sung SC; Wisniewski SR; Balasubramani GK; Zisook S; Kurian B; Warden D; Trivedi MH; Rush AJ;
    Psychol Med; 2013 May; 43(5):945-60. PubMed ID: 23228340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
    Feighner JP; Gardner EA; Johnston JA; Batey SR; Khayrallah MA; Ascher JA; Lineberry CG
    J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluoxetine and desipramine in major depressive disorder.
    Bowden CL; Schatzberg AF; Rosenbaum A; Contreras SA; Samson JA; Dessain E; Sayler M
    J Clin Psychopharmacol; 1993 Oct; 13(5):305-11. PubMed ID: 8227488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.
    Dastjerdi MS; Kazemi F; Najafian A; Mohammady M; Aminorroaya A; Amini M
    Int J Obes (Lond); 2007 Apr; 31(4):713-7. PubMed ID: 16969361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and risk factors of thyroid dysfunction in outpatients with overweight or obese first-episode and drug-naïve major depressive disorder.
    Wang Q; Xu X; Ren H; Tan L; Zhang XY
    J Affect Disord; 2023 May; 328():135-140. PubMed ID: 36806659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
    Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
    Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine.
    Lin HS; Wang FC; Lin CH
    J Clin Psychopharmacol; 2015 Dec; 35(6):661-6. PubMed ID: 26479220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder.
    Gudayol-Ferré E; Herrera-Guzmán I; Camarena B; Cortés-Penagos C; Herrera-Abarca JE; Martínez-Medina P; Cruz D; Hernández S; Genis A; Carrillo-Guerrero MY; Avilés Reyes R; Guàrdia-Olmos J
    J Affect Disord; 2010 Dec; 127(1-3):343-51. PubMed ID: 20584552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study.
    Gelenberg AJ; Dunner DL; Rothschild AJ; Pedersen R; Dorries KM; Ninan PT
    J Nerv Ment Dis; 2013 Apr; 201(4):266-73. PubMed ID: 23538970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of obesity measures in the development and persistence of major depressive disorder.
    Gibson-Smith D; Bot M; Paans NP; Visser M; Brouwer I; Penninx BW
    J Affect Disord; 2016 Jul; 198():222-9. PubMed ID: 27031289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
    Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
    J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
    Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
    Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pain has a strong negative impact on the fluoxetine response in hospitalized patients with major depressive disorder.
    Lin CH; Lane HY; Chen CC; Juo SH; Yen CF
    Clin J Pain; 2011; 27(9):805-10. PubMed ID: 21677571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
    Akiskal HS; Benazzi F; Perugi G; Rihmer Z
    J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Body mass index (BMI) in major depressive disorder and its effects on depressive symptomatology and antidepressant response.
    Dreimüller N; Lieb K; Tadić A; Engelmann J; Wollschläger D; Wagner S
    J Affect Disord; 2019 Sep; 256():524-531. PubMed ID: 31280076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study.
    Quante A; Regen F; Schindler F; Volkmer K; Severus E; Urbanek C; Luborzewski A; Roepke S; Anghelescu I
    Psychiatr Danub; 2013 Sep; 25(3):214-20. PubMed ID: 24048387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes?
    Nierenberg AA; Pava JA; Clancy K; Rosenbaum JF; Fava M
    Biol Psychiatry; 1996 Oct; 40(8):691-6. PubMed ID: 8894060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.